New Clinical Trial: Nivolumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) that have Either Failed or are Not Eligible for Autologous Stem Cell Transplant

The Weill Cornell Lymphoma Program has recently opened a new clinical trial for men and women with relapsed or refractory diffuse large B-cell lymphoma, that have either failed or are not eligible for Autologous Stem Cell Transplant. The study sponsor is Bristol-Myers Squibb, and the principal investigator at Weill Cornell is Dr. John Leonard. For more information about the study, please call Amelyn Rodgriguez, RN at (212) 746-1362 or e-mail Amelyn at

Key Eligibility

  • Men and women equal to or greater than 18 years of age
  • A performance status of 0 or 1
  • Biopsy confirmation of relapsed, refractory DLBCL, or transformed lymphoma (TL) prior to the initiation of study drug
  • Prior treatment as defined below:
    – Subjects with relapsed or refractory DLBCL or TL after high-dose conditioning chemotherapy and ASCT, or
    – Subjects with relapsed or refractory DLBCL or TL after at least 2 prior multi-agent  chemotherapy regimens if ASCT ineligible. Ineligibility for ASCT will be determined  using local institutional criteria
  • Detailed eligibility reviewed when you contact the study team

Study Details

This clinical trial is testing a drug called Nivolumab (also known as BMS-936558, a monoclonal antibody) as therapy for subjects with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) after failure of autologous stem cell transplant (ASCT). The purpose of this study is to test the effectiveness, safety, and tolerability of the investigational drug Nivolumab.

Subjects enrolled on this study will receive Nivolumab 3 mg/kg intravenously on the start of every 2 week cycle.  The study medication may be interrupted, withheld or stopped for different reasons. However, subjects will be asked to follow up periodically for two years after ending treatment.

Author: lymphomaprogram

Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible.

Post a Comment

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: